AI-powered, load-and-go platform has potential to radically shift how veterinarians process, diagnose, and act on cytology and blood morphology cases The global launch of the IDEXX (IDXX) inVue Dx ...
Double‑digit fourth‑quarter growth: IDEXX reported 14% reported (12% organic) revenue growth and $3.08 EPS (up 17% comparable), driven by record premium instrument placements (6,567 in the quarter, ...
CEO Jay Mazelsky highlighted IDEXX's solid start to 2025, with 5% organic revenue growth in Q1. The company achieved 4.5% organic growth in CAG Diagnostic recurring revenues, despite a 1.5% headwind ...
Cancer Dx expansion and inVue Dx FNA combine preventive screening and rapid, in-clinic diagnosis, enabling veterinarians and pet owners to act with confidence IDEXX Laboratories, Inc. (NASDAQ: IDXX), ...
Cancer Dx expansion and inVue Dx FNA combine preventive screening and rapid, in-clinic diagnosis, enabling veterinarians and pet owners to act with confidence Mast Cell Tumors Are Common Mast cell ...
The IDEXX Cancer Dx Panel has already transformed cancer screening for veterinarians. Today, more than 5,500 practices across the United States and Canada use the lymphoma test, which can detect the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results